Posted on April 1st, 2024

Opiate addiction is a pervasive issue that has touched countless lives across the nation. At Psychiatric Services in Spokane Valley, I understand the complexities of this condition and the challenges it presents. My approach to combating opiate addiction involves a comprehensive medication-assisted treatment (MAT) program. This blog post aims to shed light on the role of MAT in overcoming opiate addiction, providing insight into how medications like Brixadi, Suboxone, and others can be pivotal in the recovery journey.

Understanding Opiate Addiction

Opiate addiction is a multifaceted disorder characterized by a physical and psychological dependence on opioids. This condition often stems from the misuse of prescription painkillers, heroin, or synthetic opioids like fentanyl. The grip of opiate addiction is strong, with withdrawal symptoms and cravings making the path to recovery challenging. Recognizing the need for effective treatment strategies is the first step toward addressing this public health crisis.

The impact of opiate addiction extends beyond the individual, affecting families and communities. The consequences include health complications, emotional turmoil, and social and economic burdens. My goal at Psychiatric Services is to provide a supportive environment where individuals can embark on a path to recovery, using medication-assisted treatment as a cornerstone of their journey.

The Role of Medication-Assisted Treatment (MAT)

Medication-assisted treatment (MAT) is a proven approach to treating opiate addiction. It combines the use of FDA-approved medications with counseling and behavioral therapies to provide a holistic treatment plan. MAT is not a one-size-fits-all solution; rather, it is tailored to meet the unique needs of each individual. The primary goal of MAT is to stabilize the patient, reduce withdrawal symptoms, and decrease cravings, ultimately leading to a successful recovery.

At Psychiatric Services, I believe in the efficacy of MAT as a critical component of addiction treatment. My experienced team works closely with patients to develop a personalized MAT plan that addresses their specific challenges and goals. By integrating medication with comprehensive support services, we aim to empower individuals to overcome opiate addiction and reclaim their lives.

Medications Used in MAT

Several medications are utilized in MAT to target different aspects of opiate addiction. Buprenorphine, often prescribed as Suboxone, is a partial opioid agonist that helps reduce cravings and withdrawal symptoms without producing the euphoric effects of opioids. Naltrexone, available as Vivitrol, is an opioid antagonist that blocks the effects of opioids in the brain, helping to prevent relapse. Methadone is a long-acting opioid agonist that mitigates withdrawal symptoms and cravings, allowing individuals to engage in therapy and other aspects of their treatment plan.

Each medication has its unique properties and is prescribed based on the individual's specific needs and circumstances. My team at Psychiatric Services carefully monitors the use of these medications, ensuring that they are part of a comprehensive treatment plan that includes counseling and support services. By utilizing these medications effectively, we can provide a solid foundation for recovery and long-term success.

Sublocade: Monthly Injection

Sublocade should be used as part of a complete treatment program that includes counseling and psychosocial support. Sublocade is a drug-device combination product that utilizes buprenorphine and the Atrigel Delivery System in a pre-filled syringe. It is injected by a health care professional (HCP) under the skin (subcutaneously) as a solution, and the delivery system forms a solid deposit, or depot, containing buprenorphine. After initial formation of the depot, buprenorphine is released by the breakdown (biodegradation) of the depot. In clinical trials, Sublocade provided sustained therapeutic plasma levels of buprenorphine over the one-month dosing interval.

Brixadi: A New Hope in MAT

Brixadi is a newer medication in the arsenal against opiate addiction. It is a long-acting injectable form of buprenorphine that provides sustained relief from withdrawal symptoms and cravings. Brixadi is administered weekly or monthly, offering convenience and consistency for patients in treatment. Its extended-release formulation ensures a steady level of medication in the body, reducing the risk of relapse and supporting ongoing recovery efforts.

The introduction of Brixadi into MAT represents a significant advancement in the treatment of opiate addiction. Its long-acting nature allows for greater flexibility and adherence to the treatment plan, making it a valuable option for many individuals seeking recovery. At Psychiatric Services, I am excited about the potential of Brixadi to transform the lives of those struggling with opiate addiction.

Suboxone: A Proven Treatment in MAT

Suboxone is a widely used medication in MAT, combining buprenorphine and naloxone. It is effective in reducing withdrawal symptoms and cravings, while the presence of naloxone discourages misuse. Suboxone is typically prescribed as a sublingual film or tablet, taken daily under the supervision of a healthcare provider.

The success of Suboxone in MAT lies in its ability to provide a stable foundation for recovery. It allows individuals to focus on therapy and other aspects of their treatment plan without the constant battle against withdrawal symptoms and cravings. At Psychiatric Services, I have seen firsthand the positive impact Suboxone can have on the recovery journey, and I continue to advocate for its use as part of a comprehensive treatment strategy.

The Importance of Comprehensive Support

While medications like Brixadi and Suboxone are integral to MAT, they are most effective when combined with comprehensive support services. Counseling, behavioral therapies, and peer support groups are essential components of a successful treatment plan. These services address the psychological and emotional aspects of addiction, helping individuals develop coping strategies, build a support network, and work through the underlying issues that contribute to their substance use disorder.

At Psychiatric Services, I emphasize the importance of a holistic approach to treatment. My team of counselors, therapists, and support staff work collaboratively to provide a supportive environment where individuals can heal and grow. By addressing the whole person, not just the addiction, we can facilitate lasting recovery and a return to a fulfilling life.

Overcoming Stigma and Barriers to Treatment

One of the challenges in addressing opiate addiction is the stigma and barriers that prevent individuals from seeking help. Many people fear judgment or discrimination, while others may struggle to access treatment due to financial or logistical constraints. It is crucial to break down these barriers and create a culture of understanding and support for those affected by addiction.

At Psychiatric Services, I am committed to reducing stigma and increasing access to treatment. I offer a range of services to accommodate the diverse needs of my patients, and I work tirelessly to create a welcoming and nonjudgmental environment. By fostering a culture of compassion and inclusivity, we can encourage more individuals to take the first step towards recovery.

Conclusion

Opiate addiction is a formidable challenge, but it is one that can be overcome with the right support and treatment. Medication-assisted treatment, including medications like Brixadi and Suboxone, plays a vital role in the recovery process. At Psychiatric Services in Spokane Valley, I am dedicated to providing comprehensive and compassionate care to those struggling with opiate addiction. If you or a loved one is in need of support, please reach out to me at (509) 707-8581 or psychiatricservices@freditveldt.com .

Together, we can embark on a journey towards healing and a brighter future.

Legal Notice